Researchers present findings of retrospective analysis of microbicide study at international conference

NewsGuard 100/100 Score

"More than three years after reporting the primary results of HPTN 035, one of the last trials of the so-called first generation microbicides, researchers from the National Institutes of Health-funded Microbicide Trials Network (MTN) reported two new sets of findings gleaned" from the study data at the International Microbicides Conference in Sydney on Tuesday, an MTN press release states. According to a retrospective analysis of HPTN 035 data, researchers found that women who use hormonal contraception are not at an increased risk of HIV infection, but another study showed some women are more biologically susceptible to HIV infection than other women, the release notes. The press release details a number of other findings and highlights some of the "[m]ore than 40 oral and poster presentations by MTN investigators [that] have or will be presented at" the conference (4/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion